Reading: Crdo Stock Draws $289.91 Mean Target as Wall Street Sees Upside

Crdo Stock Draws $289.91 Mean Target as Wall Street Sees Upside

Published
2 min read
Advertisement

Wall Street has put a fresh number on Credo Technology Group Holding Ltd. (CRDO): a mean price target of $289.91, which points to 28.2% upside from the stock's last close at $226.19. The range is wide enough to matter. The lowest short-term target stands at $215.00, while the most optimistic one reaches $350.00.

Investors in Credo Technology Group Holding Ltd are looking at that spread because it gives a quick read on how divided analysts remain, even as the average leans higher. The 18 short-term estimates behind the mean leave a standard deviation of $35.68, which is a reminder that the consensus is not a single view but a cluster of different calls. That is why the average can look persuasive without being precise.

CRDO has already moved some of the way on its own. The stock gained 3.6% over the past four weeks, and over the past month the Zacks Consensus Estimate for the current year increased 1%. That combination helps explain why the bullish case is drawing attention now: investors are not just being shown a higher target, they are also being told that earnings expectations have been inching up.

- Advertisement -

The catch is that price targets are only as useful as the assumptions behind them, and those assumptions can be too optimistic. A mean target above the current share price says analysts see room for more gains, but it does not guarantee the stock will get there. The lower end of the range, at $215.00, is a quiet warning that not every analyst sees upside from here.

What comes next is less about the target itself and more about whether Credo Technology Group Holding Ltd can produce the kind of results that keep those estimates moving higher. For now, the number investors have is straightforward: Wall Street sees upside, but it is a view built on estimates that can change quickly if the company fails to deliver.

Advertisement
Share This Article